STEP: Proglide® Versus Femoseal®: A Trial to Compare the Efficacy of Arterial Closure Devices Following Endovascular Peripheral Arterial Procedures
- Conditions
- Peripheral Arterial Disease
- Interventions
- Other: Arterial closure to ensure hemostasis at femoral artery puncture pointsDevice: Femoseal® (Terumo)Device: Proglide® (Abbott)
- Registration Number
- NCT03192033
- Lead Sponsor
- Nantes University Hospital
- Brief Summary
Over the past years, arterial closure systems have tended to replace manual compression to ensure hemostasis at femoral artery puncture points. Arterial closure systems reduce hemostasis and patient immobilization times, thus enabling early resumption of walking. These devices have contributed extensively to the development of outpatient stays for cardiology, vascular and neuro-radiology procedures.
However, main arterial closure devices use different technology to close the arterial puncture point. For some, hemostasis is achieved by sealing the arteriotomy between two discs (an inner and an outer). For others, they are designed to close puncture sites delivering a single monofilament polypropylene suture mediated by needles.
The investigators hypothesis is based on a different efficacy between both arterial closure devices for peripheral arterial disease (PAD) patients.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 233
- Age > 18 years,
- Patient with peripheral arterial disease
- Endovascular examination or treatment compatible with a 5F to 7F sheath
- Walking ability
- Patient affiliated with a social security scheme
- Patient's signed informed consent form
- Under-age patient
- Patient of age, but under legal guardianship or care
- Contraindication to endovascular treatment
- Use of a 8F or greater sheath
- Morbidity contraindicating same-day walking
- History of ipsilateral open common femoral artery surgery
- Stent at the puncture site
- Radial or brachial puncture
- Antegrade femoral puncture
- Acute ischemia
- Life expectancy of less than one month
- Patient refusal to take part in the study
- Participation in another therapeutic trial
- Pregnant woman
- Allergy to clopidogrel or aspirin
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Arterial closure device used is Proglide® (Abbott) Arterial closure to ensure hemostasis at femoral artery puncture points - Arterial closure device used is Proglide® (Abbott) Proglide® (Abbott) - Arterial closure device used is Femoseal® (Terumo) Femoseal® (Terumo) - Arterial closure device used is Femoseal® (Terumo) Arterial closure to ensure hemostasis at femoral artery puncture points -
- Primary Outcome Measures
Name Time Method Technical success defined as hemostasis at the puncture site without major complications. Hour 5
- Secondary Outcome Measures
Name Time Method Quality of life evaluation (EQ-5D) Month 1 Cost-Outcome Ratio of patient care with FemoSeal® (St Jude) and Proglide® (Abbott) Month 1 The measure of effectiveness will be the utility obtained from the EQ-5D quality of life questionnaire
Occurrence of major punctured femoral artery events during the perioperative period Hour 5 Walking ability Hour 5 Time before restart of the ambulation measured in minutes from when the sheath of the introducer of the arterial closure system is removed and the moment when the patient is able to walk 100 meters without the recurrence of bleeding.
Occurrence of minor punctured femoral artery events during the perioperative period Hour 5 Occurrence of major cardio-vascular events Month 1
Trial Locations
- Locations (6)
CH de Cholet
🇫🇷Cholet, France
CHU Brest
🇫🇷Brest, France
CHD La Roche-sur-Yon
🇫🇷La Roche-sur-Yon, France
CHU de Poitiers
🇫🇷Poitiers, France
CHU Angers
🇫🇷Angers, France
CHU de Rennes
🇫🇷Rennes, France